MCP
CYTK icon

Mirador Capital Partners’s Cytokinetics CYTK Stock Holding History

Mirador Capital Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.2M Sell
202,370
-303
-0.1% -$21.8K 2.11% 11
2026
Q1 		$13.4M Buy
202,673
+4,115
+2% +$262K 1.89% 13
2025
Q4 		$12.6M Buy
198,558
+1,191
+0.6% +$74.1K 1.73% 14
2025
Q3 		$10.8M Buy
197,367
+53,020
+37% +$2.18M 1.54% 18
2025
Q2 		$4.77M Buy
144,347
+45,222
+46% +$1.57M 0.77% 33
2025
Q1 		$3.98M Buy
99,125
+33,489
+51% +$1.54M 0.7% 37
2024
Q4 		$3.09M Buy
65,636
+1,010
+2% +$52.5K 0.56% 41
2024
Q3 		$3.41M Buy
64,626
+1,483
+2% +$82.7K 0.61% 42
2024
Q2 		$3.42M Buy
63,143
+27,688
+78% +$1.67M 0.64% 40
2024
Q1 		$2.49M Sell
35,455
-13,497
-28% -$1.04M 0.47% 49
2023
Q4 		$4.09M Sell
48,952
-6,676
-12% -$242K 0.87% 30
2023
Q3 		$1.64M Buy
55,628
+1,890
+4% +$62.9K 0.37% 60
2023
Q2 		$1.75M Sell
53,738
-2,846
-5% -$105K 0.42% 61
2023
Q1 		$1.99M Sell
56,584
-2,148
-4% -$87.6K 0.47% 52
2022
Q4 		$2.69M Sell
58,732
-69,753
-54% -$3M 0.64% 39
2022
Q3 		$6.22M Sell
128,485
-35,098
-21% -$1.69M 1.5% 17
2022
Q2 		$6.43M Buy
163,583
+4,085
+3% +$164K 1.52% 18
2022
Q1 		$5.87M Buy
159,498
+6,879
+5% +$244K 1.19% 21
2021
Q4 		$6.96M Sell
152,619
-10,857
-7% -$419K 1.46% 19
2021
Q3 		$5.84M Buy
163,476
+4,977
+3% +$147K 1.33% 21
2021
Q2 		$3.14M Buy
158,499
+9,415
+6% +$221K 0.71% 46
2021
Q1 		$3.47M Sell
149,084
-3,311
-2% -$70.7K 0.89% 37
2020
Q4 		$3.17M Buy
152,395
+40,271
+36% +$736K 0.87% 41
2020
Q3 		$2.43M Buy
112,124
+16,017
+17% +$375K 0.76% 44
2020
Q2 		$2.27M Sell
96,107
-1,247
-1% -$23.4K 0.85% 39
2020
Q1 		$1.62M Sell
97,354
-5,122
-5% -$65.3K 0.68% 46
2019
Q4 		$1.09M Buy
+102,476
New +$1.05M 0.44% 64

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mirador Capital Partners's CYTK Position: Q2 2026 in Review

Mirador Capital Partners reduced its Cytokinetics (CYTK) stake by 0.15% in Q2 2026, selling an estimated $21.8K and leaving 202,370 shares worth $17.2M. The position accounts for 2.11% of the portfolio, ranked #11.

Mirador Capital Partners first reported a position in CYTK in Q4 2019 and has held it in 27 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Mirador Capital Partners held 202,370 shares of Cytokinetics worth $17.2M as of Q2 2026.
  • Mirador Capital Partners sold 303 Cytokinetics shares in Q2 2026, an estimated $21.8K.
  • Cytokinetics made up 2.11% of Mirador Capital Partners's portfolio in Q2 2026, its #11 holding.
  • Mirador Capital Partners first reported a position in Cytokinetics in Q4 2019 and has held it in 27 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Mirador Capital Partners's 13F filing for Q2 2026, filed 7 Jul 2026.